Nam Hae-Seong
Center for Lung Cancer and Division of Pulmonary, Department of Internal Medicine, Inha University Hospital, Inha University College of Medicine, Incheon, Korea.
Tuberc Respir Dis (Seoul). 2014 May;76(5):211-7. doi: 10.4046/trd.2014.76.5.211. Epub 2014 May 29.
Malignant pleural effusions (MPEs) are the second leading cause of exudative pleural effusions after parapneumonic effusions. In the vast majority of cases, a MPE signifies incurable disease associated with high morbidity and mortality. Considerable advances have been made for the diagnosis of MPEs, through the development of improved methods in the specialized cytological and imaging studies. The cytological or histological confirmation of malignant cells is currently important in establishing a diagnosis. Furthermore, despite major advancements in cancer treatment for the past two decades, management of MPE remains palliative. This article presents a comprehensive review of the medical approaches for diagnosis and management of MPE.
恶性胸腔积液（MPEs）是继类肺炎性胸腔积液之后渗出性胸腔积液的第二大常见病因。在绝大多数情况下，MPE意味着与高发病率和死亡率相关的不治之症。通过在专门的细胞学和影像学研究中开发改进方法，MPE的诊断取得了相当大的进展。目前，恶性细胞的细胞学或组织学确认对于确诊至关重要。此外，尽管在过去二十年中癌症治疗取得了重大进展，但MPE的管理仍然是姑息性的。本文对MPE的诊断和管理的医学方法进行了全面综述。
